AB&B Bio-Tech's Flu Vaccine Shortlisted for Insurance Coverage in China
MT Newswires Live
Aug 13
AB&B Bio-Tech (HKG:2627) said Chinese authorities have placed its flagship flu vaccine on a preliminary list for possible insurance coverage, according to a Hong Kong bourse filing Wednesday.
The company's quadrivalent subunit influenza vaccine, Huierkangxin, made it to the National Healthcare Security Administration's preliminary list for insurance reimbursement and was the only product of its kind to do so, AB&B Bio-Tech said.
Huierkangxin remains the first and only quadrivalent subunit influenza vaccine to be approved in China as of July 21, AB&B Bio-Tech said.
Shares of the pharmaceutical company jumped 13% in Wednesday morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.